Revisited 2026 evidence leaves routine care unchanged for most adults with persistent acne. Clascoterone cream 1% (Winlevi), a topical drug that blocks androgen receptors in skin, remains a case-by-case option rather than a new first-line treatment. Persistent acne in adults often needs steady multimodal care, not a single swap. The key questions are how clascoterone works, how well it worked in trials, and why guidelines still favor established regimens.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What makes clascoterone different?
- How well did it work in trials?
- Why do guidelines still favor established care?
- What should adults with persistent acne do now?
What makes clascoterone different?
Clascoterone competes with androgens for skin androgen receptors to reduce sebum production and inflammation. The MDPI Pharmaceuticals narrative review describes that mechanism as distinct from retinoids, benzoyl peroxide, and antibiotics.
Drugs.com's FDA history reports that the FDA approved Winlevi on August 26, 2020 for acne vulgaris in patients age 12 and older as a first-in-class topical androgen-receptor inhibitor, described in the FDA approval history. That first-in-class status matters because it targets oil and inflammation through hormones in skin, not through exfoliation, bacteria, or oxidation.
How well did it work in trials?
In two identical Phase 3 trials, patients with moderate-to-severe facial acne applied clascoterone or vehicle twice daily for 12 weeks. Pooled data in 1,421 patients age 12 and older showed treatment success in 19.9% with clascoterone versus 7.7% with vehicle, plus greater inflammatory and noninflammatory lesion reductions.
The pooled Hebert analysis, summarized in the Dove Medical Press review, reports the difference as highly statistically significant, detailed in the pooled hormonal-therapy review. The result supports real benefit, but success rates remained modest and vehicle response explains part of the change.
Why do guidelines still favor established care?
The 2024 American Academy of Dermatology acne guideline gives clascoterone only a conditional recommendation despite rating evidence certainty as high, because high price may impair equitable access. Managed Healthcare Executive's report on the guideline ties that caution directly to cost and access, explained in the AAD guideline cost analysis.
For most adults, the AAD still strongly recommends topical retinoids, benzoyl peroxide, their fixed-dose combinations, topical antibiotic combinations, and oral isotretinoin for severe disease. A direct comparison is also missing: a 2024 systematic review across 6 trials with 5,474 patients found no significant efficacy difference among clascoterone, trifarotene, and tazarotene, and safety in pregnancy and lactation remains unknown.
What should adults with persistent acne do now?
Keep the proven base first: a topical retinoid plus benzoyl peroxide regimen, often as a fixed-dose or carefully layered combination. Consider clascoterone as a possible add-on for persistent disease, especially jawline acne in adult women where androgen signaling may contribute.
Use this checklist before asking a clinician about it: Clascoterone was generally well tolerated with mainly local irritation, but FDA labeling notes reversible HPA-axis suppression in 1 of 20 adults and 2 of 22 adolescents at Day 14, all normal 4 weeks after stopping. Bring your current products, prior irritation, and treatment history to that visit.
- Can you sustain twice-daily application for at least 12 weeks
- What is the out-of-pocket cost and insurance coverage
- Will it replace or join retinoid, benzoyl peroxide, or other therapy
- What is the plan for maintenance if acne improves
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- High-Glycemic Diets and Acne Evidence Revisited in 2026: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Spironolactone, Metformin, and Bicalutamide for Acne in a 2026 Review: Who Was Studied and Who Was Not for Adults With Persistent Acne